JP2019521986A - 多重特異性抗体の精製 - Google Patents

多重特異性抗体の精製 Download PDF

Info

Publication number
JP2019521986A
JP2019521986A JP2018565786A JP2018565786A JP2019521986A JP 2019521986 A JP2019521986 A JP 2019521986A JP 2018565786 A JP2018565786 A JP 2018565786A JP 2018565786 A JP2018565786 A JP 2018565786A JP 2019521986 A JP2019521986 A JP 2019521986A
Authority
JP
Japan
Prior art keywords
chromatography
antibody
mixed mode
anion exchange
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018565786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521986A5 (enExample
Inventor
グレン スコット ギース，
グレン スコット ギース，
エーファ ローゼンベルガー，
エーファ ローゼンベルガー，
ベルナール サリエル，
ベルナール サリエル，
ズザンネ コンラート，
ズザンネ コンラート，
ヴォルフガング ケーンライン，
ヴォルフガング ケーンライン，
シュテッフェン ヴィルマン，
シュテッフェン ヴィルマン，
アガーテ ビアラス，
アガーテ ビアラス，
キンバリー アン カレアス−キャロル，
キンバリー アン カレアス−キャロル，
インゲス イグゾー，
インゲス イグゾー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2019521986A publication Critical patent/JP2019521986A/ja
Publication of JP2019521986A5 publication Critical patent/JP2019521986A5/ja
Priority to JP2022117433A priority Critical patent/JP7564843B2/ja
Priority to JP2024102664A priority patent/JP7881651B2/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Water Supply & Treatment (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2018565786A 2016-06-17 2017-06-16 多重特異性抗体の精製 Pending JP2019521986A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022117433A JP7564843B2 (ja) 2016-06-17 2022-07-22 多重特異性抗体の精製
JP2024102664A JP7881651B2 (ja) 2016-06-17 2024-06-26 多重特異性抗体の精製

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351908P 2016-06-17 2016-06-17
US62/351,908 2016-06-17
PCT/US2017/038007 WO2017218977A2 (en) 2016-06-17 2017-06-16 Purification of multispecific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022117433A Division JP7564843B2 (ja) 2016-06-17 2022-07-22 多重特異性抗体の精製

Publications (2)

Publication Number Publication Date
JP2019521986A true JP2019521986A (ja) 2019-08-08
JP2019521986A5 JP2019521986A5 (enExample) 2020-08-06

Family

ID=59593150

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018565786A Pending JP2019521986A (ja) 2016-06-17 2017-06-16 多重特異性抗体の精製
JP2022117433A Active JP7564843B2 (ja) 2016-06-17 2022-07-22 多重特異性抗体の精製
JP2024102664A Active JP7881651B2 (ja) 2016-06-17 2024-06-26 多重特異性抗体の精製

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022117433A Active JP7564843B2 (ja) 2016-06-17 2022-07-22 多重特異性抗体の精製
JP2024102664A Active JP7881651B2 (ja) 2016-06-17 2024-06-26 多重特異性抗体の精製

Country Status (18)

Country Link
US (1) US20190256556A1 (enExample)
EP (2) EP4549463A3 (enExample)
JP (3) JP2019521986A (enExample)
KR (3) KR102826635B1 (enExample)
CN (1) CN109563124A (enExample)
AR (1) AR108800A1 (enExample)
AU (2) AU2017286676B2 (enExample)
BR (1) BR112018075516A2 (enExample)
CA (1) CA3026518A1 (enExample)
ES (1) ES2988363T3 (enExample)
HR (1) HRP20241323T1 (enExample)
HU (1) HUE068564T2 (enExample)
IL (1) IL263690B2 (enExample)
MX (2) MX2018015173A (enExample)
PL (1) PL3472177T3 (enExample)
SG (1) SG11201810777WA (enExample)
TW (1) TWI798179B (enExample)
WO (1) WO2017218977A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022191158A1 (ja) * 2021-03-09 2022-09-15 Ｊｃｒファーマ株式会社 抗体－リソソーム酵素融合蛋白質の製造方法
WO2022225060A1 (ja) * 2021-04-23 2022-10-27 協和キリン株式会社 分解物の産生を抑制する方法
JP2023510382A (ja) * 2020-01-15 2023-03-13 エフ． ホフマン－ラ ロシュ アーゲー 組換えタンパク質製造プロセスから不純物を減少させる方法
JP2023542079A (ja) * 2020-09-21 2023-10-05 ジェネンテック， インコーポレイテッド 多重特異性抗体の精製
JP2024500747A (ja) * 2020-12-18 2024-01-10 キニクサ ファーマシューティカルズ， リミテッド タンパク質組成物ならびにそれを産生及び使用するための方法
JP2024539136A (ja) * 2021-10-19 2024-10-28 アルテオジェン・インコーポレイテッド ＩｇＧ Ｆｃドメインを有する融合タンパク質の精製方法

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
WO2019043096A1 (en) * 2017-08-30 2019-03-07 Fresenius Kabi Deutschland Gmbh METHOD FOR PURIFYING IL-6 ANTI-RECEPTOR ANTIBODIES
US11945839B2 (en) 2017-12-22 2024-04-02 Hoffmann-La Roche Inc. Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
WO2019149691A1 (en) * 2018-01-30 2019-08-08 Univercells S.A. Protein purification process
WO2019149693A1 (en) * 2018-01-30 2019-08-08 Univercells S.A. Protein purification process and platform
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
US20230182041A1 (en) * 2018-04-25 2023-06-15 Medimmune, Llc Purification of antibodies
CN119033684A (zh) 2018-10-29 2024-11-29 豪夫迈·罗氏有限公司 抗体制剂
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
KR20210121137A (ko) 2019-01-29 2021-10-07 샤이어-엔피에스 파마슈티칼즈, 인크. 부갑상선 호르몬 변이체
AU2020268896B2 (en) 2019-05-03 2024-11-28 F. Hoffmann-La Roche Ag Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
CN114026108B (zh) * 2019-06-28 2024-09-10 夏尔巴生物技术(苏州)有限公司 无缝连续流层析方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2022554283A (ja) * 2019-11-07 2022-12-28 アムジエン・インコーポレーテツド 生成物関連不純物を除去するためのカチオン交換クロマトグラフィー中の高塩分洗浄
WO2021099536A1 (en) * 2019-11-22 2021-05-27 Morphosys Ag Method to increase antibody yield during ion exchange chromatography
KR102154952B1 (ko) * 2020-02-21 2020-09-10 프레스티지바이오로직스 주식회사 아달리무맙의 Non-Protein A 정제방법
WO2021170060A1 (en) * 2020-02-28 2021-09-02 Wuxi Biologics (Shanghai) Co., Ltd. Purification of bispeciifc antibodies
WO2021181417A1 (en) * 2020-03-11 2021-09-16 Dr. Reddy's Laboratories Limited METHOD OF PURIFYING AN Fc-FUSION PROTEIN
CN115734969A (zh) * 2020-04-13 2023-03-03 上海药明生物技术有限公司 双特异性抗体的纯化
US20230143066A1 (en) * 2020-04-17 2023-05-11 Ono Pharmaceutical Co., Ltd. Method for removing color from drug substance of protein preparation
CN113563469A (zh) * 2020-04-28 2021-10-29 江苏中新医药有限公司 高回收率纯化阿达木单抗的方法
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
AU2021265346A1 (en) * 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of affinity chromatography
CA3182314A1 (en) * 2020-05-01 2021-11-04 Kashiv Biosciences, Llc An improved process of purification of protein
WO2021220500A1 (ja) * 2020-05-01 2021-11-04 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 帯電物質の精製方法
CN114014906B (zh) * 2020-06-24 2024-01-12 夏尔巴生物技术(苏州)有限公司 一种利用阳离子交换层析纯化疏水性蛋白的方法
CN114539416B (zh) * 2020-11-26 2024-11-08 盛禾(中国)生物制药有限公司 一种双特异性抗体的层析纯化工艺
SMT202500333T1 (it) 2020-12-18 2025-11-10 Richter Gedeon Nyrt Metodi per la purificazione di proteina di fusione fc-peptide
CN117242095A (zh) * 2021-04-23 2023-12-15 和铂医药(上海)有限责任公司 一种双特异性抗体的纯化方法
WO2022272119A2 (en) * 2021-06-25 2022-12-29 The Board Of Trustees Of The University Of Illinois Synthetic toolkit for plant transformation
WO2024076990A1 (en) * 2022-10-03 2024-04-11 Therini Bio, Inc. Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use
CN117990807B (zh) * 2022-11-07 2024-09-24 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体电荷异质性的检测方法
CN119264256B (zh) * 2023-07-07 2026-01-02 齐鲁制药有限公司 一种单克隆抗体的纯化方法
CN116769044A (zh) * 2023-07-11 2023-09-19 康日百奥生物科技(苏州)有限公司 抗cd3和cd19双特异性抗体蛋白及其层析纯化方法
WO2025029614A1 (en) * 2023-07-28 2025-02-06 Amgen Inc. A method for equilibrating a chromatography medium
WO2025088516A1 (en) * 2023-10-26 2025-05-01 Pfizer Inc. Method of forming multi-specific antibodies from homodimer antibodies and pharmaceutical product including multi-specific antibodies thus obtained
WO2025155751A1 (en) * 2024-01-17 2025-07-24 Nutcracker Therapeutics, Inc. Improved method for isolating and characterizing proteins
CN122060072A (zh) * 2026-03-16 2026-05-19 齐鲁制药有限公司 一种法瑞西单抗的纯化方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015070068A1 (en) * 2013-11-07 2015-05-14 Abbvie Inc. Isolation and purification of antibodies
WO2016018740A2 (en) * 2014-07-26 2016-02-04 Regeneron Pharmaceuticals, Inc. Purification platform for bispecific antibodies

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541A (en) 1837-12-26 Daniel desmond
US7521A (en) 1850-07-22 Improvement in the
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
EP1356052B1 (en) 2000-12-14 2008-08-20 Genentech, Inc. Production of full antibodies in procaryotic cells
ES2376454T3 (es) 2000-12-22 2012-03-14 Grad, Carole, Legal Representative Of Howard, Kaplan Librer�?as de expresión en fago de fragmentos vh humanos.
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
JP5087274B2 (ja) 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
KR101150050B1 (ko) * 2004-02-27 2012-07-05 지이 헬스케어 바이오-사이언시스 에이비 항체 정제 방법
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
CN100475965C (zh) 2005-07-22 2009-04-08 上海高科联合生物技术研发有限公司 一种大肠杆菌高效外分泌表达溶葡萄球菌酶的方法
KR20140053410A (ko) * 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
DE102008048942B4 (de) 2008-09-25 2011-01-13 Siemens Aktiengesellschaft Anordnung mit einer Wellendichtung
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
SG176219A1 (en) 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
HRP20171095T4 (hr) 2010-05-25 2022-07-22 F. Hoffmann - La Roche Ag Postupci pročišćavanja polipeptida
BR112013002167A2 (pt) * 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
WO2012059495A1 (en) * 2010-11-05 2012-05-10 F. Hoffmann-La Roche Ag Optimized method for antibody capturing by mixed mode chromatography
CN103429620B (zh) * 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
EP2578286A1 (en) * 2011-10-04 2013-04-10 Merck Patent GmbH Method and apparatus for chromatographic purification
SI2766397T1 (sl) 2011-10-11 2018-09-28 F. Hoffmann-La Roche Ag Izboljšano sestavljanje bispecifičnih protiteles
SI3495387T1 (sl) * 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
KR102250937B1 (ko) * 2012-09-11 2021-05-12 코히러스 바이오사이언시즈, 인코포레이티드 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트
CN118271429A (zh) * 2013-08-19 2024-07-02 豪夫迈·罗氏有限公司 用羟基磷灰石层析分离双特异性抗体和双特异性抗体生产副产物
WO2015061526A1 (en) * 2013-10-25 2015-04-30 Medimmune, Llc Antibody purification
EP3116891B1 (en) * 2014-03-10 2020-02-12 Richter Gedeon Nyrt. Immunoglobulin purification using pre-cleaning steps
ES3053874T3 (en) * 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015070068A1 (en) * 2013-11-07 2015-05-14 Abbvie Inc. Isolation and purification of antibodies
WO2016018740A2 (en) * 2014-07-26 2016-02-04 Regeneron Pharmaceuticals, Inc. Purification platform for bispecific antibodies

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023510382A (ja) * 2020-01-15 2023-03-13 エフ． ホフマン－ラ ロシュ アーゲー 組換えタンパク質製造プロセスから不純物を減少させる方法
JP7801227B2 (ja) 2020-01-15 2026-01-16 エフ． ホフマン－ラ ロシュ アーゲー 組換えタンパク質製造プロセスから不純物を減少させる方法
JP2023542079A (ja) * 2020-09-21 2023-10-05 ジェネンテック， インコーポレイテッド 多重特異性抗体の精製
JP7871252B2 (ja) 2020-09-21 2026-06-08 ジェネンテック， インコーポレイテッド 多重特異性抗体の精製
JP2024500747A (ja) * 2020-12-18 2024-01-10 キニクサ ファーマシューティカルズ， リミテッド タンパク質組成物ならびにそれを産生及び使用するための方法
WO2022191158A1 (ja) * 2021-03-09 2022-09-15 Ｊｃｒファーマ株式会社 抗体－リソソーム酵素融合蛋白質の製造方法
JP2022138142A (ja) * 2021-03-09 2022-09-22 Ｊｃｒファーマ株式会社 抗体－リソソーム酵素融合蛋白質の製造方法
JP7881327B2 (ja) 2021-03-09 2026-06-29 Ｊｃｒファーマ株式会社 抗体－リソソーム酵素融合蛋白質の製造方法
WO2022225060A1 (ja) * 2021-04-23 2022-10-27 協和キリン株式会社 分解物の産生を抑制する方法
JP2024539136A (ja) * 2021-10-19 2024-10-28 アルテオジェン・インコーポレイテッド ＩｇＧ Ｆｃドメインを有する融合タンパク質の精製方法

Also Published As

Publication number Publication date
CN109563124A (zh) 2019-04-02
BR112018075516A2 (pt) 2019-10-01
WO2017218977A3 (en) 2018-01-18
AU2024227572A1 (en) 2024-11-14
AU2017286676A8 (en) 2018-12-20
IL263690A (en) 2019-01-31
IL263690B1 (en) 2023-01-01
SG11201810777WA (en) 2018-12-28
MX2024003651A (es) 2024-04-15
IL263690B2 (en) 2023-05-01
KR20190039929A (ko) 2019-04-16
MX2018015173A (es) 2019-07-04
KR20250107275A (ko) 2025-07-11
JP2022166004A (ja) 2022-11-01
WO2017218977A2 (en) 2017-12-21
JP2024156655A (ja) 2024-11-06
EP3472177B1 (en) 2024-08-14
AU2017286676A1 (en) 2018-12-13
CA3026518A1 (en) 2017-12-21
TW201803902A (zh) 2018-02-01
WO2017218977A8 (en) 2019-03-28
JP7564843B2 (ja) 2024-10-09
TWI798179B (zh) 2023-04-11
ES2988363T3 (es) 2024-11-20
HUE068564T2 (hu) 2025-01-28
HRP20241323T1 (hr) 2024-12-20
KR102826635B1 (ko) 2025-06-30
PL3472177T3 (pl) 2024-11-25
AU2017286676B2 (en) 2024-07-25
AR108800A1 (es) 2018-09-26
KR20230113662A (ko) 2023-07-31
EP3472177A2 (en) 2019-04-24
EP4549463A2 (en) 2025-05-07
JP7881651B2 (ja) 2026-06-29
US20190256556A1 (en) 2019-08-22
EP4549463A3 (en) 2025-07-30
EP3472177C0 (en) 2024-08-14

Similar Documents

Publication Publication Date Title
JP7564843B2 (ja) 多重特異性抗体の精製
US20240101714A1 (en) Assembly of bispecific antibodies
TW202346350A (zh) 製造抗體之方法
US20230220114A1 (en) Purification of multispecific antibodies
BR122025028953A2 (pt) Métodos para purificação de um anticorpo multiespecífico, de um polipeptídeo heterodimérico contendo fc e de um anticorpo biespecífico que se liga a ang-2 e vegf, para produção de um polipeptídeo heterodimérico contendo fc e de um anticorpo biespecífico que se liga a ang-2 e vegf, e para fabricação de um medicamento ou uma composição para tratamento de câncer ou doença ocular, bem como composições, e uso de um anticorpo multiespecífico
HK1230663B (en) Methods and compositions for secretion of heterologous polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220722

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220729

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220802

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220922

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240826